Study of FID-022 in Participants With Advanced Solid Tumors
NCT06694480
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
24
Enrollment
INDUSTRY
Sponsor class
Conditions
Advanced Solid Tumors
Interventions
DRUG:
FID-022
Sponsor
Fulgent Pharma LLC.